For the past few days I think the shorts have started to bring the stock down only to see that later on others who have a better idea of what is coming down the line scooping up more shares.
Are there any other stocks that have an equivalent risk/reward profile as VRTX that you could recommend taking a look at? I would appreciate hearing your thoughts. Have owned VRTX for many many years.
Excellent find qdelfan. Thanks.
Barber says Vertex didn’t make an announcement because “formulation work and regulatory discussions have been ongoing” since the deal was struck, and it “wanted to communicate about the VX-210 program when we had further clarity on the development program and next steps.”
Vertex expects to provide those details when it starts the next trial of the drug later this year, he says.
Mentioned in VRTX annual report released earlier this week. The market likes it.
Gene editing using CRISPR technology in higher animals and plants is very new, and potentially allows fixing genetic problems at the very root. Today people are talking about an exact CRISPR procedure to repair the sickle cell anemia gene. It can delete sections of the genome with precision. And a gene engineering could refill the void with normal codes in the future.
It is amusing to think about CRISPR/Cas9 techniques as new technology because bacteria have been using the method for a billion years to fight off bacteriophage infection. About ten years ago, researchers found that the bacteria carried CRISPR [Clustered Regularly Interspaced Short Palindromic Repeats] sequence in their DNA body. It took a few more years to figure out the reason. It turned out that the repeated genetic codes contained the code of phage which had attacked the bacteria before, and when attacked again by the same phage, the code sequence would be transcribed into RNA, then chopped into small pieces, each containing phage gene codes. Then Cas9 nuclease goes into action by cleaving the bonds holding the phage DNA double strands where the chopped RNA recognizes as the phage gene. Next Cas9 shreds the phage DNA and kills the phage. So, CRISPR/Cas9 is an immune system for the bacteria.
Only less than two years ago, a few groups reported that they can cut to produce a DNA double-strand break in human or mouse embryonic cells, and some reported that they repaired the cut with another gene segment to produce a new organism. They say that the technique is simple, fast, and reliable that any graduate student in biology can master it to apply to different model systems. If so, could this system be used to treat genetic abnormalities in human? Some challenges are still remaining, but those too may be overcome in future.